Xi-Yu Liu
Overview
Explore the profile of Xi-Yu Liu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
335
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sui X, Cao S, Song X, Liu X, Chen C, Yan Q, et al.
Biomark Res
. 2025 Feb;
13(1):29.
PMID: 39948640
No abstract available.
2.
Sui X, Cao S, Song X, Liu X, Chen C, Yan Q, et al.
Biomark Res
. 2025 Jan;
13(1):6.
PMID: 39780291
Background: Although immunotherapy has achieved great progress in advanced triple-negative breast cancer (TNBC), there are still numerous patients who do not benefit from immunotherapy. Therefore, identification of the key molecule...
3.
He M, Jiang Y, Gong Y, Fan L, Liu X, Liu Y, et al.
BMJ
. 2024 Oct;
387:e079603.
PMID: 39442958
Objective: To evaluate the feasibility of using a multigene signature to tailor individualised adjuvant therapy for patients with operable triple negative breast cancer. Design: Randomised, multicentre, open label, phase 3...
4.
Liu X, Wang X
BMC Endocr Disord
. 2024 Apr;
24(1):51.
PMID: 38654232
Objectives: In comparison to the subjects without diabetes, a greater concentration of serum carbohydrate antigen 19 - 9 (CA 19 - 9) was observed in the subjects with diabetes. Nevertheless,...
5.
Fan L, Wang Z, Ma L, Wu S, Wu J, Yu K, et al.
Lancet Oncol
. 2024 Jan;
25(2):184-197.
PMID: 38211606
Background: Triple-negative breast cancers display heterogeneity in molecular drivers and immune traits. We previously classified triple-negative breast cancers into four subtypes: luminal androgen receptor (LAR), immunomodulatory, basal-like immune-suppressed (BLIS), and...
6.
Ge L, Jin X, Ma D, Wang Z, Liu C, Zhou C, et al.
Cell Res
. 2024 Jan;
34(1):58-75.
PMID: 38168642
Triple-negative breast cancer (TNBC) is an aggressive disease characterized by remarkable intratumor heterogeneity (ITH), which poses therapeutic challenges. However, the clinical relevance and key determinant of ITH in TNBC are...
7.
Chen C, Lin C, Pei Y, Ma D, Liao L, Li S, et al.
Cell Discov
. 2023 Dec;
9(1):125.
PMID: 38114467
Germline-somatic mutation interactions are universal and associated with tumorigenesis, but their role in breast cancer, especially in non-Caucasians, remains poorly characterized. We performed large-scale prospective targeted sequencing of matched tumor-blood...
8.
Hu Q, Tong Z, Yalikong A, Ge L, Shi Q, Du X, et al.
Nat Chem
. 2023 Sep;
16(1):122-131.
PMID: 37710046
Biomarker discovery is essential for the understanding, diagnosis, targeted therapy and prognosis assessment of malignant diseases. However, it remains a huge challenge due to the lack of sensitive methods to...
9.
Zhang Z, Wu Q, Ren A, Chen Q, Shi J, Li J, et al.
Acta Pharmacol Sin
. 2023 Jun;
44(11):2282-2295.
PMID: 37280363
Abnormalities of FGFR1 have been reported in multiple malignancies, suggesting FGFR1 as a potential target for precision treatment, but drug resistance remains a formidable obstacle. In this study, we explored...
10.
Liu X, Zhou Y
J Diabetes Investig
. 2022 Dec;
14(3):429-434.
PMID: 36510700
Aims/introduction: Diabetes and hepatitis B are both global problems. The influence of diabetes on complications and prognosis of hepatitis B has been widely studied. However, the association between hepatitis B...